Waldenstrom’s macroglobulinemia

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Waldenstrom’s macroglobulinemia is an indolent B-cell malignancy defined by a lymphoplasmacytic infiltration in the bone marrow or in other organs including lymph nodes, liver, and spleen, as well as a monoclonal immunoglobulin M protein (IgM) in the serum. The infiltration of the bone marrow and extramedullary sites by malignant B lymphocytes, as well as elevated IgM levels, typically leads to symptoms associated with this disease. While Waldenstrom’s macroglobulinemia typically follows an indolent course, the disease remains incurable with current therapy. Due to the heterogeneous clinical presentation, the presence of multiple comorbidities and competing causes of death, the decision to treat patients as well as the choice of treatment can be complex as many patients do not require treatment initially. When patients do require therapy, it is important to select therapies that do not limit future treatment options. To provide a simple risk-adapted approach to managing patients with Waldenstrom’s macroglobulinemia, a rational approach to this disease is presented.

Original languageEnglish (US)
Title of host publicationBiology and Management of Unusual Plasma Cell Dyscrasias
PublisherSpringer New York
Pages71-93
Number of pages23
ISBN (Electronic)9781441968487
ISBN (Print)9781441968470
DOIs
StatePublished - Jan 1 2016

Fingerprint

Waldenstrom Macroglobulinemia
Immunoglobulin M
B-Lymphocytes
Therapeutics
Bone Marrow
Comorbidity
Blood Proteins
Cause of Death
Spleen
Lymph Nodes
Liver
Neoplasms
Proteins

Keywords

  • Igm
  • Lymphoplasmacytic lymphoma
  • MGUS
  • MYD88
  • Waldenstrom’s macroglobulinemia

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ansell, S. M. (2016). Waldenstrom’s macroglobulinemia. In Biology and Management of Unusual Plasma Cell Dyscrasias (pp. 71-93). Springer New York. https://doi.org/10.1007/978-1-4419-6848-7_4

Waldenstrom’s macroglobulinemia. / Ansell, Stephen Maxted.

Biology and Management of Unusual Plasma Cell Dyscrasias. Springer New York, 2016. p. 71-93.

Research output: Chapter in Book/Report/Conference proceedingChapter

Ansell, SM 2016, Waldenstrom’s macroglobulinemia. in Biology and Management of Unusual Plasma Cell Dyscrasias. Springer New York, pp. 71-93. https://doi.org/10.1007/978-1-4419-6848-7_4
Ansell SM. Waldenstrom’s macroglobulinemia. In Biology and Management of Unusual Plasma Cell Dyscrasias. Springer New York. 2016. p. 71-93 https://doi.org/10.1007/978-1-4419-6848-7_4
Ansell, Stephen Maxted. / Waldenstrom’s macroglobulinemia. Biology and Management of Unusual Plasma Cell Dyscrasias. Springer New York, 2016. pp. 71-93
@inbook{402273af373841d09e6e091f25f3d2bb,
title = "Waldenstrom’s macroglobulinemia",
abstract = "Waldenstrom’s macroglobulinemia is an indolent B-cell malignancy defined by a lymphoplasmacytic infiltration in the bone marrow or in other organs including lymph nodes, liver, and spleen, as well as a monoclonal immunoglobulin M protein (IgM) in the serum. The infiltration of the bone marrow and extramedullary sites by malignant B lymphocytes, as well as elevated IgM levels, typically leads to symptoms associated with this disease. While Waldenstrom’s macroglobulinemia typically follows an indolent course, the disease remains incurable with current therapy. Due to the heterogeneous clinical presentation, the presence of multiple comorbidities and competing causes of death, the decision to treat patients as well as the choice of treatment can be complex as many patients do not require treatment initially. When patients do require therapy, it is important to select therapies that do not limit future treatment options. To provide a simple risk-adapted approach to managing patients with Waldenstrom’s macroglobulinemia, a rational approach to this disease is presented.",
keywords = "Igm, Lymphoplasmacytic lymphoma, MGUS, MYD88, Waldenstrom’s macroglobulinemia",
author = "Ansell, {Stephen Maxted}",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-1-4419-6848-7_4",
language = "English (US)",
isbn = "9781441968470",
pages = "71--93",
booktitle = "Biology and Management of Unusual Plasma Cell Dyscrasias",
publisher = "Springer New York",

}

TY - CHAP

T1 - Waldenstrom’s macroglobulinemia

AU - Ansell, Stephen Maxted

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Waldenstrom’s macroglobulinemia is an indolent B-cell malignancy defined by a lymphoplasmacytic infiltration in the bone marrow or in other organs including lymph nodes, liver, and spleen, as well as a monoclonal immunoglobulin M protein (IgM) in the serum. The infiltration of the bone marrow and extramedullary sites by malignant B lymphocytes, as well as elevated IgM levels, typically leads to symptoms associated with this disease. While Waldenstrom’s macroglobulinemia typically follows an indolent course, the disease remains incurable with current therapy. Due to the heterogeneous clinical presentation, the presence of multiple comorbidities and competing causes of death, the decision to treat patients as well as the choice of treatment can be complex as many patients do not require treatment initially. When patients do require therapy, it is important to select therapies that do not limit future treatment options. To provide a simple risk-adapted approach to managing patients with Waldenstrom’s macroglobulinemia, a rational approach to this disease is presented.

AB - Waldenstrom’s macroglobulinemia is an indolent B-cell malignancy defined by a lymphoplasmacytic infiltration in the bone marrow or in other organs including lymph nodes, liver, and spleen, as well as a monoclonal immunoglobulin M protein (IgM) in the serum. The infiltration of the bone marrow and extramedullary sites by malignant B lymphocytes, as well as elevated IgM levels, typically leads to symptoms associated with this disease. While Waldenstrom’s macroglobulinemia typically follows an indolent course, the disease remains incurable with current therapy. Due to the heterogeneous clinical presentation, the presence of multiple comorbidities and competing causes of death, the decision to treat patients as well as the choice of treatment can be complex as many patients do not require treatment initially. When patients do require therapy, it is important to select therapies that do not limit future treatment options. To provide a simple risk-adapted approach to managing patients with Waldenstrom’s macroglobulinemia, a rational approach to this disease is presented.

KW - Igm

KW - Lymphoplasmacytic lymphoma

KW - MGUS

KW - MYD88

KW - Waldenstrom’s macroglobulinemia

UR - http://www.scopus.com/inward/record.url?scp=85006378267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006378267&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-6848-7_4

DO - 10.1007/978-1-4419-6848-7_4

M3 - Chapter

AN - SCOPUS:85006378267

SN - 9781441968470

SP - 71

EP - 93

BT - Biology and Management of Unusual Plasma Cell Dyscrasias

PB - Springer New York

ER -